EGFR and colorectal carcinoma: Compared with the inhibition of a single pathway, the combination of VEGF antisense oligonucleotides and cetuximab to block VEGF and EGFR enhanced the antitumor activity and improve the survival rate in mice carrying CRC xenografts of human GEO colon cancer cells (14).